New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Ermina StratinaCarol StanciuRobert NastasaSebastian ZenoviaRemus StafieAdrian RotaruTudor CuciureanuCristina Maria MuzicaCatalin Victor SfartiIrina GîrleanuHoria MineaOana Cristina PetreaLaura HuibanStefan ChiriacAna-Maria SingeapOana VladCamelia CojocariuAnca Victorița TrifanPublished in: Diagnostics (Basel, Switzerland) (2024)
The superior metabolic effects of semaglutide, correlated to dapagliflozin, may contribute to a more efficient decrease in hepatic stress and injury, leading to a substantial enhancement of liver function in T2DM patients. Further investigations conducted over an ideal timeframe are necessary to confirm the evidence presented in this study.